Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material

MYPI2025000774A0Undetermined Publication Date: 2024-02-03SUNTORY HLDG LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000774
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-03
Filing Date
2023-07-25
Publication Date
2024-02-03

AI Technical Summary

Technical Problem

Ergothioneine and its salts have a bitter taste and milk-derived ceramide-containing materials have a distinct odor, making them challenging to incorporate into oral compositions effectively.

Method used

Combining ergothioneine or its salt with a milk-derived ceramide-containing material in specific weight ratios, typically between 2:70, suppresses the bitterness and odor, with preferred ratios for ceramide-containing whey powder and sphingomyelin content, to create a more palatable oral composition.

Benefits of technology

The method effectively reduces the bitter taste and odor, making it easier to continuously ingest ergothioneine or its salt and milk-derived ceramide-containing materials, enhancing their usability in food, cosmetic, and pharmaceutical products.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention aims to provide an oral composition, which contains ergothioneine or a salt thereof and a milk-derived ceramide-containing material, with reduced bitterness derived from the ergothioneine or a salt thereof and reduced odor derived from the milk-derived ceramide-containing material. The present invention also aims to provide a method for reducing bitterness derived from ergothioneine or a salt thereof and odor derived from a milk-derived ceramide-containing material. The present invention relates to an oral composition containing components (A) and (B) defined as follows: (A) ergothioneine or a salt thereof; and (B) milk-derived ceramide-containing material, wherein a weight ratio (B) / (A) of the component (A) in terms of ergothioneine to the component (B) is 2 to 70.
Need to check novelty before this filing date? Find Prior Art

Description

Oral composition and method for suppressing bitterness derived from ergothioneine or its salt and odor derived from milk-derived ceramide-containing material

[0001] The present invention relates to an oral composition and a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material.

[0002] Ergothioneine is a hydrophilic sulfur-containing amino acid known to have various physiological activities, including antioxidant activity. Regarding the physiological activities of ergothioneine, for example, Patent Document 1 reports that it has the effect of activating immune responses and promoting cytokine production. Due to its diverse physiological activities, ergothioneine has recently attracted attention for use in foods, cosmetics, and pharmaceuticals.

[0003] Sphingomyelin contained in milk is a precursor of ceramide and a type of sphingolipid containing sphingo bases. Materials containing sphingomyelin derived from milk are called milk ceramides.

[0004] Japanese Patent Application Laid-Open No. 2017-218431

[0005] As described above, ergothioneine has useful physiological activities, and therefore, foods such as supplements containing ergothioneine or its salts are useful for maintaining or improving health. Furthermore, milk-derived ceramide-containing materials have been suggested to have a skin moisturizing effect. Therefore, it is believed that various useful effects can be expected by ingesting an oral composition containing ergothioneine or its salts and a milk-derived ceramide-containing material. However, ergothioneine or its salts have a unique flavor, particularly a stinging bitterness, which leaves room for improvement when used in oral compositions. Furthermore, milk-derived ceramide-containing materials have a unique odor (a fishy, ​​milky odor), which can be problematic when incorporated into oral compositions.

[0006] An object of the present invention is to provide an oral composition that contains ergothioneine or a salt thereof and a milk-derived ceramide-containing material, while suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material. Another object of the present invention is to provide a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material.

[0007] As a result of intensive research conducted by the present inventors to solve the above-mentioned problems, they discovered that by combining ergothioneine or a salt thereof with a milk-derived ceramide-containing material in a specific ratio, it is possible to suppress the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material.

[0008] The present invention includes, but is not limited to, the following oral compositions and methods for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material. [1] An oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a milk-derived ceramide-containing material, wherein the weight ratio of component (B) to component (A) (in ergothioneine equivalent) ((B) / (A)) is 2 to 70. [2] The composition according to [1] above, wherein the weight ratio of component (B) to component (A) (in ergothioneine equivalent) ((B) / (A)) is 3 to 60. [3] The composition according to [1] or [2] above, wherein the milk-derived ceramide-containing material (B) is a ceramide-containing whey powder. [4] The composition according to any one of [1] to [3] above, wherein the (B) milk-derived ceramide-containing material contains (C) sphingomyelin, and the weight ratio of the (C) sphingomyelin to the component (A) (in terms of ergothioneine), ((C) / (A)), is 0.01 to 10. [5] The composition according to any one of [1] to [4] above, wherein the milk is cow's milk. [6] The composition according to any one of [1] to [5] above, which is a food or drink. [7] A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a milk-derived ceramide-containing material, by adjusting the weight ratio of the component (B) to the component (A) (in terms of ergothioneine), ((B) / (A)), to 2 to 70.

[0009] According to the present invention, an oral composition can be provided that contains ergothioneine or a salt thereof and a milk-derived ceramide-containing material, while suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material. Furthermore, according to the present invention, a method can be provided for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material.

[0010] The oral composition of the present invention contains (A) ergothioneine or a salt thereof (component (A)), and (B) a milk-derived ceramide-containing material (component (B)), and the weight ratio of component (B) to component (A) (in terms of ergothioneine), ((B) / (A)), is 2 to 70.

[0011] Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acid salt or a basic salt. Examples of acid salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.

[0012] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.

[0013] In the present invention, the milk-derived ceramide-containing material refers to a milk-derived material containing (C) sphingomyelin. Milk is preferably cow's milk. In the present invention, the milk-derived ceramide-containing material is preferably a ceramide-containing material derived from milk. Ceramide-containing materials derived from milk are called milk ceramides. The milk-derived ceramide-containing material may be a mixture of milk phospholipids (lipids), carbohydrates, and proteins.

[0014] The oral composition of the present invention may contain a commercially available milk ceramide as a milk-derived ceramide-containing material, including those prepared by known methods.

[0015] The milk-derived ceramide-containing material preferably has a sphingomyelin content of 0.5% by weight or more, more preferably 1 to 30% by weight, even more preferably 1 to 10% by weight, and particularly preferably 1 to 5% by weight.

[0016] Ceramide-containing whey powder is preferred as the milk-derived ceramide-containing material (B). Commercially available ceramide-containing whey powders (e.g., Milk Ceramide MC-5, manufactured by Megmilk Snow Brand Co., Ltd., Milk Ceramide PLC, manufactured by Tatua Cooperative Dairy Co., Ltd.) can be used. Ceramide-containing whey powder can also be prepared by the method described in JP 2007-89535 A, for example.

[0017] In the oral composition of the present invention, the ratio ((B) / (A)) of the weight of (B) the milk-derived ceramide-containing material (component (B)) to the weight of (A) ergothioneine or a salt thereof (component (A)) converted into ergothioneine is 2 to 70. Ergothioneine or a salt thereof has a bitter taste that stings the tongue. In addition, the milk-derived ceramide-containing material has a characteristic fishy, ​​milky odor. In a composition containing components (A) and (B), when the weight ratio ((B) / (A)) of component (B) to component (A) (converted into ergothioneine) is within the above range, the bitterness derived from component (A) can be suppressed, and the odor derived from component (B) can also be effectively suppressed. This facilitates continuous intake of ergothioneine or a salt thereof and the milk-derived ceramide-containing material. The weight ratio ((B) / (A)) is preferably 3 or more, more preferably 4 or more, even more preferably 5 or more, and preferably 60 or less, more preferably 55 or less, and even more preferably 50 or less. In one embodiment, the weight ratio of component (B) to component (A) (in terms of ergothioneine), ((B) / (A)), is preferably 3 to 60, more preferably 4 to 55, and even more preferably 5 to 50. When the amount of ergothioneine or a salt thereof in terms of ergothioneine is referred to as an amount equivalent to ergothioneine, in the case of ergothioneine salts, it means the amount of ergothioneine. In the case of ergothioneine salts, it means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.

[0018] In the oral composition of the present invention, the weight ratio ((C) / (A)) of (C) sphingomyelin (component (C)) to component (A) (in terms of ergothioneine) is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, still more preferably 0.1 or more, and is preferably 10 or less, more preferably 5 or less, even more preferably 2 or less, even more preferably 1.5 or less, and particularly preferably 1 or less. In one embodiment, the weight ratio ((C) / (A)) of (C) sphingomyelin to (A) ergothioneine or a salt thereof (component (A)) (in terms of ergothioneine) is preferably 0.01 to 10, more preferably 0.03 to 10, even more preferably 0.03 to 5, even more preferably 0.03 to 2, even more preferably 0.03 to 1.5, particularly preferably 0.05 to 1.5, and most preferably 0.1 to 1.

[0019] The content of ergothioneine or a salt thereof in the oral composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the oral composition of the present invention, in terms of ergothioneine, is, for example, preferably 0.1 wt% or more, more preferably 0.5 wt% or more, even more preferably 1 wt% or more, and preferably 33 wt% or less, more preferably 20 wt% or less, even more preferably 17 wt% or less, and particularly preferably 10 wt% or less. In one embodiment, the content of ergothioneine or a salt thereof in the composition of the present invention, in terms of ergothioneine, is preferably 0.1 to 33 wt%, more preferably 0.5 to 20 wt%, even more preferably 1 to 17 wt%, and particularly preferably 1 to 10 wt%. When the composition of the present invention contains two or more compounds as ergothioneine or a salt thereof, the content of ergothioneine or a salt thereof is the total content thereof. The content of ergothioneine can be measured by high-performance liquid chromatography (HPLC).

[0020] The content of the milk-derived ceramide-containing material in the oral composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of the milk-derived ceramide-containing material in the oral composition of the present invention may be, for example, 0.01 wt % or more, preferably 0.2 wt % or more, more preferably 1.0 wt % or more, or 99 wt % or less, preferably 95 wt % or less, more preferably 90 wt % or less, even more preferably 85 wt % or less, and even more preferably 50 wt % or less. In one aspect, the content of the milk-derived ceramide-containing material in the oral composition of the present invention is, for example, preferably 0.01 to 99 wt %, preferably 0.01 to 95 wt %, more preferably 0.2 to 90 wt %, even more preferably 1.0 to 85 wt %, and even more preferably 1.0 to 50 wt %. When the composition of the present invention contains two or more materials as the milk-derived ceramide-containing material, the content of the milk-derived ceramide-containing material is the total content of those materials.

[0021] The content of sphingomyelin in the oral composition of the present invention is, for example, preferably 0.0001% by weight or more, more preferably 0.002% by weight or more, even more preferably 0.01% by weight or more, and preferably 10% by weight or less, more preferably 5% by weight or less, even more preferably 4% by weight or less, even more preferably 3% by weight or less, and particularly preferably 2% by weight or less. In one aspect, the content of sphingomyelin in the oral composition of the present invention is, for example, preferably 0.0001 to 10% by weight, more preferably 0.002 to 5% by weight, even more preferably 0.01 to 4% by weight, even more preferably 0.01 to 3% by weight, and particularly preferably 0.01 to 2% by weight. The content of sphingomyelin can be measured by HPLC.

[0022] The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 1 to 100 mg, more preferably 2 to 50 mg, even more preferably 5 to 25 mg, and particularly preferably 5 to 20 mg, of ergothioneine per daily intake for an adult.

[0023] The composition of the present invention preferably contains 2 to 5,000 mg of the milk-derived ceramide-containing material, more preferably 4 to 1,000 mg, even more preferably 10 to 500 mg, and particularly preferably 25 to 250 mg, per daily intake for an adult. The composition of the present invention also preferably contains 0.04 to 1,000 mg of sphingomyelin, more preferably 0.08 to 20 mg, even more preferably 0.2 to 10 mg, and particularly preferably 0.5 to 5 mg, per daily intake for an adult.

[0024] Ergothioneine or a salt thereof and a milk-derived ceramide-containing material are compounds that are contained in natural products and foods and beverages and are commonly consumed as food. Therefore, from the viewpoint of safety, it is believed that ergothioneine or a salt thereof and a milk-derived ceramide-containing material pose few problems even when ingested daily. According to the present invention, it is possible to provide a composition that is highly safe and easy to ingest, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material are suppressed.

[0025] As described above, ergothioneine or a salt thereof is known to exhibit a variety of physiological activities and health functions, such as antioxidant activity, brain function improving effect, anti-aging effect, eye disease improving effect, whitening effect, ultraviolet absorption effect, melanin production suppression effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc. Therefore, the composition of the present invention can be suitably used for antioxidant activity, brain function improving effect, anti-aging effect, eye disease, whitening effect, ultraviolet absorption effect, melanin production suppression, reactive oxygen species scavenging effect, elastase activity inhibition effect, wrinkle formation suppression effect, skin sagging suppression effect, autophagy promotion effect, etc.

[0026] Milk-derived ceramide-containing materials have been suggested to have a skin moisturizing effect. Since the composition of the present invention contains a milk-derived ceramide-containing material, it can also be used to obtain the above-mentioned effects exerted by the milk-derived ceramide-containing material.

[0027] The composition of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes. Non-therapeutic is a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis. The composition of the present invention is a composition that is taken orally. Specific examples of oral compositions include foods and beverages, oral pharmaceuticals, quasi-drugs, and feed. The composition of the present invention may be a material or formulation to be incorporated into these. The composition of the present invention is preferably a food and beverage or oral pharmaceutical, and more preferably a food and beverage.

[0028] The composition of the present invention may contain any additives and any ingredients in addition to ergothioneine or a salt thereof and a milk-derived ceramide-containing material, as long as the effects of the present invention are not impaired. These additives and ingredients can be selected depending on the form of the composition, and those generally usable for oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used. In one aspect, the composition of the present invention may consist of ergothioneine or a salt thereof and a milk-derived ceramide-containing material. The form of the oral composition of the present invention is not particularly limited and may be a solid (powder, granules, tablet, etc.), liquid, paste, etc.

[0029] In one aspect, when the composition of the present invention is used as a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof and a milk-derived ceramide-containing material with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples thereof include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0030] When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and a milk-derived ceramide-containing material can be blended with a pharmacologically acceptable carrier, additives added as needed, and the like to produce pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, and the like may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, and the like.

[0031] When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and a milk-derived ceramide-containing material may be blended into the feed. The feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0032] The subject to which the composition of the present invention is ingested or administered (also referred to as the administration subject) is not particularly limited, and is preferably a human or a non-human mammal, more preferably a human.

[0033] The method for producing the oral composition of the present invention is not particularly limited, and the composition can be produced, for example, by blending (A) ergothioneine or a salt thereof and (B) a milk-derived ceramide-containing material into the composition so that the weight ratio between them falls within the above-mentioned range. In preparing an oral composition containing (A) ergothioneine or a salt thereof and (B) a milk-derived ceramide-containing material, by adjusting the weight ratio ((B) / (A)) of component (B) to component (A) (in ergothioneine terms) to 2 to 70, an oral composition can be obtained in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material are suppressed. The weight ratio can be adjusted by adjusting the amount of each component blended.

[0034] The present invention also encompasses the following method: A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material in an oral composition containing (A) ergothioneine or a salt thereof (component (A)) and (B) a milk-derived ceramide-containing material (component (B)), by adjusting the weight ratio of component (B) to component (A) (in ergothioneine equivalent) ((B) / (A)) to 2 to 70. By adjusting the weight ratio of component (B) to component (A) (in ergothioneine equivalent) ((B) / (A)) within the above range in the preparation of the oral composition, an oral composition can be obtained in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material are suppressed.

[0035] The above method makes it possible to effectively suppress the bitterness derived from ergothioneine or a salt thereof and the odor derived from the milk-derived ceramide-containing material. By suppressing the unpleasant flavors (bitterness and odor) derived from ergothioneine or a salt thereof and the milk-derived ceramide-containing material, the taste of the oral composition can be improved. In the above method, the ergothioneine or a salt thereof, the milk-derived ceramide-containing material, and preferred embodiments thereof are the same as those in the oral composition of the present invention described above. The preferred range of the weight ratio ((B) / (A)) of component (B) to component (A) (in ergothioneine equivalent) is also the same as that in the oral composition of the present invention. The content of (C) sphingomyelin (component (C)) in the milk-derived ceramide-containing material and the preferred range of the weight ratio ((C) / (A)) of component (C) to component (A) (in ergothioneine equivalent) are also the same as those in the composition of the present invention described above.

[0036] The above-mentioned method can suppress the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material, but may be combined with other bitterness suppression methods and / or odor suppression methods, such as a method of adding a sweetener or a flavoring agent to a bitter or odorous component to prepare a formulation, a method of coating a bitter or odorous component with a sugar coating to prepare a formulation, or a method of encapsulating the component to prepare a formulation.

[0037] The milk-derived ceramide-containing material is useful for suppressing the bitterness of ergothioneine or a salt thereof. The present invention also encompasses use of the milk-derived ceramide-containing material for suppressing the bitterness derived from ergothioneine or a salt thereof. The amount of the milk-derived ceramide-containing material used is preferably such that the weight ratio ((B) / (A)) of the milk-derived ceramide-containing material (B) to the ergothioneine or a salt thereof (as ergothioneine) is 2 to 70.

[0038] Ergothioneine or a salt thereof is useful for suppressing the odor of a milk-derived ceramide-containing material. The present invention also encompasses the use of ergothioneine or a salt thereof for suppressing the odor of a milk-derived ceramide-containing material. The amount of ergothioneine or a salt thereof used is preferably an amount such that the weight ratio ((B) / (A)) of (A) ergothioneine or a salt thereof (in ergothioneine equivalent) to (B) the milk-derived ceramide-containing material is 2 to 70.

[0039] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.

[0040] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0041] The raw materials used in the evaluation tests below are as follows: (A) Ergothioneine: A raw material containing 100% L-ergothioneine (B) Milk-derived ceramide-containing material: Ceramide-containing whey powder containing 2% by weight of sphingomyelin (Milk Ceramide PLC, manufactured by Tatsuta Co-operative Dairy Co., Ltd.) (B) Milk-derived ceramide-containing material does not contain dextrin.

[0042] Example 1 Compositions of Samples 1 to 6 (compositions containing ergothioneine and a milk-derived ceramide-containing material) were prepared by mixing the raw materials (A) and (B) in the amounts shown in Table 1. The weight ratios of (B) / (A) in the compositions of Samples 1 to 6 are shown in Table 1. "(C) sphingomyelin (mg)" in Table 1 is the content of sphingomyelin in the sample. The weight ratios of (C) sphingomyelin / (A) ergothioneine ((C) / (A)) in the compositions of Samples 1 to 6 are also shown in Table 1.

[0043] Three panelists skilled in sensory evaluation each placed the entire amount of the prepared composition (for example, for Sample 1, a total of 20 mg consisting of 10 mg of ergothioneine and 10 mg of the milk-derived ceramide-containing material) directly on their tongues and evaluated the intensity of the bitterness derived from ergothioneine and the intensity of the odor derived from the milk-derived ceramide-containing material according to the following criteria.

[0044] (A) Evaluation criteria for bitterness derived from ergothioneine The bitterness derived from ergothioneine was evaluated using the following criteria on a scale of 1 to 5 (5 levels). As the reference point, the bitterness intensity of (A) ergothioneine alone (10 mg) was set at 5 points (Control 1). The evaluations of three panelists were compiled, and the average values ​​are shown in the evaluation results in Table 1. 5 points: The bitterness derived from ergothioneine is strongly felt 4 points: The bitterness derived from ergothioneine is felt 3 points: The bitterness derived from ergothioneine is slightly felt 2 points: The bitterness derived from ergothioneine is not felt very much 1 point: The bitterness derived from ergothioneine is not felt

[0045] (B) Evaluation criteria for odor derived from milk-derived ceramide-containing material The odor derived from the milk-derived ceramide-containing material was evaluated using the following criteria on a scale of 1 to 5 (5 levels). As the reference point, the intensity of the odor (fishy, ​​milky odor) of the above (B) milk-derived ceramide-containing material alone (10 mg, containing 0.2 mg of sphingomyelin) was assigned 5 points (Control 2). The evaluations of three panelists were compiled, and the average values ​​are shown in the evaluation results in Table 1. 5 points: Strong odor derived from the milk-derived ceramide-containing material 4 points: Odor derived from the milk-derived ceramide-containing material 3 points: Slight odor derived from the milk-derived ceramide-containing material 2 points: Little odor derived from the milk-derived ceramide-containing material 1 point: No odor derived from the milk-derived ceramide-containing material

[0046] When the average scores for the evaluation of the bitterness derived from ergothioneine and the evaluation of the odor derived from the milk-derived ceramide-containing material were both 3.0 points or less, it was determined that the bitterness derived from ergothioneine and the odor derived from the milk-derived ceramide-containing material were suppressed.

[0047]

[0048] When the milk-derived ceramide-containing material was not blended, the stinging bitter taste derived from ergothioneine was strongly felt (Control 1). On the other hand, when only the milk-derived ceramide-containing material was blended, the odor derived from the milk-derived ceramide-containing material was strongly felt (Control 2). In Samples 2 to 4 and 6, both the bitter taste derived from ergothioneine and the odor derived from the milk-derived ceramide-containing material were effectively alleviated.

Claims

1. An oral composition comprising the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a milk-derived ceramide-containing material, wherein the weight ratio of component (B) to component (A) (in terms of ergothioneine), ((B) / (A)), is 2 to 70.

2. The composition according to claim 1, wherein the weight ratio ((B) / (A)) of component (B) to component (A) (in terms of ergothioneine) is 3 to 60.

3. A composition according to claim 1 or 2, wherein (B) the milk-derived ceramide-containing material is a ceramide-containing whey powder.

4. A composition according to claim 1 or 2, wherein the milk-derived ceramide-containing material (B) contains sphingomyelin (C), and the weight ratio ((C) / (A)) of sphingomyelin (C) to component (A) (in terms of ergothioneine) is 0.01 to 10.

5. The composition according to claim 1 or 2, wherein the milk is cow's milk.

6. The composition according to claim 1 or 2, which is a food or drink.

7. A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from a milk-derived ceramide-containing material, in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) a milk-derived ceramide-containing material, by adjusting the weight ratio ((B) / (A)) of component (B) to component (A) (in ergothioneine equivalent) to 2 to 70.